Academic-Industrial Partnership to Develop Clinical Tools for Algorithmic Irreversible Electroporation of Inoperable Tumors

学术与工业合作开发用于不可手术肿瘤的算法不可逆电穿孔的临床工具

基本信息

项目摘要

Project Summary / Abstract An estimated 100,000 patients are diagnosed with primary liver or pancreatic cancer per year with an even larger number of patients will developing liver metastasis. Unfortunately, the vast majority of these patients are not candidates for surgical resection, which is the only reliably curative treatment, yielding a five year survival rate of approximately between 10 and 20% for patients with primary disease. The clinical challenge is that most tumors form deep within organs, near major blood vessels, bile ducts, or nerves which complicate surgical removal. Algorithmically Controlled Electroporation (ACE) is a new minimally invasive technique invented by the PI for the treatment of inoperable tumors. This treatment uses brief electrical pulses to destabilize the cell membrane and induce a tunable combination of necrotic and apoptotic cell death. We have validated the anti- cancer efficacy of ACE against in vitro models, small animal tumor models, and in over 80 veterinary clinical cases. In this Academic-Industrial Partnership proposal we will transition this validated technology from bench to bedside through the development of a clinical instrument and matching disposable applicators. This instrumentation will be validated in a porcine liver model to generate data necessary for 510(k) regulatory submissions. The anti-tumor efficacy of the new system will then be demonstrated in a cohort of 22 canine liver cancer patients admitted to the NCSU College of Veterinary Medicine. Data from this study will support premarket approval (PMA) regulatory submissions targeting an oncology indication and provide the necessary data to justify human clinical trials. To accomplish these goals we have assembled a multi-disciplinary team of biomedical engineers, immunologists, veterinarians, hepatobiliary pathologists, and interventional oncologists. Development work for the clinical system and the disposable applicators will be completed by two industrial partners: Gradient Medical Inc. and Nocturnal Product Development LLC. These partners have extensive experience in the development of pulsed electric field devices, commercialization of Class I, II, & III medical devices, quality systems management (GMP/GLP) as well as CE, 510(k), and PMA regulatory submissions. The proposed work will result in the development of a complete medical device suitable for clinical trials and commercialization along with the data necessary to support submission of FDA regulatory filings. This work will be accomplished via four specific aims: (1) Characterization of Metrics for Real Time Treatment Monitoring, (2) Design and Validate Clinical ACE Pulse Generation System Suitable for Regulatory Evaluation, (3) Characterization of ACE Treatments In a Large Animal Clinical Model, (4) Evaluate Safety and Efficacy of ACE Against Spontaneous Canine Hepatocellular Carcinoma.
项目摘要/摘要

项目成果

期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Michael Benjamin Sano其他文献

Michael Benjamin Sano的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Michael Benjamin Sano', 18)}}的其他基金

Development of an INSPIRE System for the Treatment of Inoperable Liver Tumors
开发用于治疗无法手术的肝脏肿瘤的 INSPIRE 系统
  • 批准号:
    10560677
  • 财政年份:
    2023
  • 资助金额:
    $ 51.4万
  • 项目类别:
Academic-Industrial Partnership to Develop Clinical Tools for Algorithmic Irreversible Electroporation of Inoperable Tumors
学术与工业合作开发用于不可手术肿瘤的算法不可逆电穿孔的临床工具
  • 批准号:
    10504276
  • 财政年份:
    2022
  • 资助金额:
    $ 51.4万
  • 项目类别:

相似海外基金

ホウ素中性子捕捉療法におけるabscopal effect機序の初期探索研究
硼中子俘获治疗远隔效应机制的初步探索性研究
  • 批准号:
    24K18767
  • 财政年份:
    2024
  • 资助金额:
    $ 51.4万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Abscopal effect of 131I-MIBG therapy for refractory neuroblastoma
131I-MIBG 治疗难治性神经母细胞瘤的远隔效应
  • 批准号:
    20K22836
  • 财政年份:
    2020
  • 资助金额:
    $ 51.4万
  • 项目类别:
    Grant-in-Aid for Research Activity Start-up
Local oncolytic adenovirotherapy inducing the direct abscopal effect via exosome
局部溶瘤腺病毒疗法通过外泌体诱导直接远隔效应
  • 批准号:
    20K17617
  • 财政年份:
    2020
  • 资助金额:
    $ 51.4万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation for epigenetic mechanism of Abscopal effect in rectal cancer after CRT
阐明直肠癌 CRT 后远隔效应的表观遗传机制
  • 批准号:
    18K16279
  • 财政年份:
    2018
  • 资助金额:
    $ 51.4万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of a mechanism of abscopal effect -Innovative cancer treatment strategy-
阐明远隔效应的机制-创新的癌症治疗策略-
  • 批准号:
    18H02696
  • 财政年份:
    2018
  • 资助金额:
    $ 51.4万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
The abscopal effect of nanosecond electric pulse tumor ablation and its enhancement for metastatic breast cancer
纳秒电脉冲肿瘤消融及其强化治疗转移性乳腺癌的远隔效应
  • 批准号:
    9756343
  • 财政年份:
    2018
  • 资助金额:
    $ 51.4万
  • 项目类别:
Consideration of effectiveness of intra-abdominal hyperthermia chemotherapy devised from abscopal effect
从远隔效应角度探讨腹腔热化疗的有效性
  • 批准号:
    18K08592
  • 财政年份:
    2018
  • 资助金额:
    $ 51.4万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Development of a new cancer treatment method using semiconductor lasers and investigation of the abscopal effect
使用半导体激光器开发新的癌症治疗方法并研究远隔效应
  • 批准号:
    18K17222
  • 财政年份:
    2018
  • 资助金额:
    $ 51.4万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
CT detection of primary and metastatic tumor and their treatment abscopal effect via radiation
原发性和转移性肿瘤的CT检测及其放射治疗远隔效应
  • 批准号:
    17K10489
  • 财政年份:
    2017
  • 资助金额:
    $ 51.4万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Exploratory Optimization of Organs for Radiotherapy or Cancer Vaccination by Abscopal Effect
通过远隔效应探索性优化放疗或癌症疫苗接种的器官
  • 批准号:
    17K10473
  • 财政年份:
    2017
  • 资助金额:
    $ 51.4万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了